Insmed Begins Trial With Iplex
Insmed will start a 24-week, multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial with Iplex in patients with myotonic muscular dystrophy.
The decision to start the trial is based on results from an ongoing open-label, dose-escalation trial of Iplex in this indication.
The study will include 60 patients and will see whether there is a 75-meter difference in the change in distance walked during the six-minute walk test between Iplex and placebo. The results from this study will be used to establish the design for Phase III development, Insmed said.